Non-Hodgkin’s Lymphoma

P2, N=31, Not yet recruiting, Ruijin Hospital

P1, N=20, Not yet recruiting, City of Hope Medical Center

P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting

Survival analyses revealed that co-high expression of SRSF1, HNRNPF, or PTBP1 and oncogenic MYC predicts poor clinical outcomes in MCL patients. Our data describe the clinical significance of aberrant SRSF1, hnRNP F, and PTBP1 in MCL and their tumor-promoting roles via the regulation of cancer hallmarks, which could be important in understanding MCL pathogenesis and therapeutic development.

Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.

AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.

P2, N=59, Active, not recruiting, Dizal Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 59 | Trial completion date: Apr 2028 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Jan 2026

P2, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Aug 2028 --> Jun 2029 | Trial primary completion date: Aug 2028 --> Jun 2029

BsAbs such as epcoritamab, glofitamab, and mosunetuzumab have demonstrated substantial efficacy across both aggressive and indolent B-cell non-Hodgkin lymphomas (B-NHL), with largely manageable safety profiles...Approaches incorporating BsAbs into cytotoxic backbones and antibody-drug conjugates, as well as chemotherapy-free regimens such as BsAbs combined with lenalidomide, are discussed...BsAbs represent a major advance in B-NHL, offering high rates of deep remission with predictable safety and outpatient feasibility. As trial data continues to mature, BsAb-based regimens are poised to become foundational across multiple lines of therapy, reshaping expectations for patients with both aggressive and indolent lymphomas.

In order to improve the efficacy, recent studies have confirmed that the combination of etoposide (CHOPE regimen) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged ≤ 65 years...The patient received four cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET/CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.

Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol...Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.

Prior psoriasis treatments included ultraviolet B phototherapy, methotrexate, ciclosporin and acitretin. At cancer diagnosis, 10 patients (20%) were on tumour necrosis factor (TNF)-α inhibitors, 8 (16%) on interleukin (IL)-17 inhibitors, five (10%) on IL-12/23 inhibitors, 5 (10%) on IL-23 inhibitors, 6 (12%) on methotrexate, 2 (4%) on apremilast and 1 (2%) on ciclosporin...Multidisciplinary collaboration and shared decision making are essential. Clinicians should consider biologic therapies for patients with both malignancy and uncontrolled psoriasis, tailoring treatments to patient-specific factors and malignancy type.